CXCongcong Xu

Congcong Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Congcong Xu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Bingting Pan

    Department of Neonatology, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Zhejiang, China

    1 shared publication
  • Huilin Yue

    Department of Neonatology, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Zhejiang, People’s Republic of China

    1 shared publication
  • Jiawen Zheng

    Department of Urology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

    1 shared publication
  • Jingjing Lin

    The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China

    1 shared publication
  • Luyao Li

    Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Hangzhou Zhejiang China

    1 shared publication
  • Qian Wang

    Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Zhejiang, China

    1 shared publication

Latest Publications

  • Open Access

    Protectin DX Relieve Hyperoxia‐induced Lung Injury by Protecting Pulmonary Endothelial Glycocalyx

    by Zhongjie Liang, Huilin Yue, Congcong Xu, Qian Wang, Shengwei Jin

    Background: Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in premature infants with limited treatments and poor prognosis. Damaged endothelial glycocalyx leads to vascular permeability, lung edema and inflammation. However, whether hyperoxia increases neonatal pulmonary microvascular permeability by degrading the endothelial glycocalyx remains unknown. Methods: Newborn mice were maintained in 60– 70% O2 for 7 days. Protectin DX (PDX), an endogenous lipid mediator, was injected intraperitoneally on postnatal d 0, 2, 4 and 6. Lung samples and bronchoalveolar lavage fluid were taken at the end of the study. Primary human umbilical vein endothelial cells (HUVECs) were cultured in 80%O2. Results: Hyperoxia exposure for 7 days led to neonatal mice alveolar simplification with less radial alveolar count (RAC), mean linear intercept (MLI) and mean alveolar diameter (MAD) compared to the control group. Hyperoxia exposure increased lung vascular permeability with more fluid and proteins and inflammatory factors, including TNF-α and IL-1β, in bronchoalveolar lavage fluid while reducing the heparan sulfate (HS), the most abundant component of the endothelial glycocalyx, in the pulmonary endothelial cells. PDX relieve these changes. PDX attenuated hyperoxia-induced high expression of heparanase (HPA), the endoglycosidase that shed endothelial glycocalyx, p‐P65, P65, and low expression of SIRT1. BOC‐2 and EX527 abolished the affection of PDX both in vivo and intro. Conclusion: In summary, our findings indicate that PDX treatment relieves hyperoxia‐induced alveolar simplification, vascular leakage and lung inflammation by attenuating pulmonary endothelial glycocalyx injury via the SIRT1/NF‐κB/ HPA pathway.


  • Open Access

    Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia‐Induced Bronchopulmonary Dysplasia via the KLF2‐Mediated Mechanism

    by Xinye Wang, Ran Huo, Zhongjie Liang, Congcong Xu, Tingting Chen, Jingjing Lin, Luyao Li, Wei Lin, Bingting Pan, Xiaoqin Fu, et al.

    Bronchopulmonary dysplasia (BPD) is a chronic lung disease commonly found in premature infants. Excessive inflammation and oxidative stress contribute to BPD occurrence and development. Simvastatin, as an inhibitor of HMG‐CoA reductase, has been reported to have antioxidative and anti‐inflammatory effects. However, its effect and possible mechanisms in hyperoxia‐induced lung injury are rarely reported. In this study, in vivo and in vitro experiments were conducted to investigate whether simvastatin could ameliorate hyperoxia‐induced lung injury and explore its potential mechanism. For the in vivo study, simvastatin could improve alveolar development after hyperoxic lung injury and reduce hyperoxic stress and inflammation. The in vitro study revealed that simvastatin can reduce inflammation in A549 cells after high‐oxygen exposure. Simvastatin suppressed NLRP3 inflammasome activation and played anti‐inflammatory and antioxidant roles by increasing KLF2 (Krüppel‐like factor 2) expression. In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia‐induced bronchopulmonary dysplasia via KLF2‐mediated mechanism.